GlassScriptPhysician profile
Lindsay Morgan Dyer
NPI 1225726714
$1,618.75
in general payments reported to CMS, 2019-2025
17 companies · $581 in 2025
The $581 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $354 · 2024: $684 · 2025: $581.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,619.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,618.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $425.73 | 2023-2025 | |
| Lilly USA, LLC | $229.37 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $223.45 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $137.47 | 2023-2025 | Breztri, Airsupra |
| Axsome Therapeutics, INC. | $121.14 | 2024-2025 | Auvelity |
| Corcept Therapeutics | $75.87 | 2024 | Korlym |
| Exact Sciences Corporation | $70.06 | 2024-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $67.88 | 2023 | Dexcom G7 Gss (161) |
| Baxter Healthcare | $67.08 | 2025 | Hillrom - Cardiac Ambulatory Monitor, Hillrom - Carnation Ambulatory Monitor |
| Novo Nordisk INC | $55.05 | 2024-2025 | Ozempic, Rybelsus |
| Ironshore Pharmaceuticals INC. | $24.95 | 2023 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $23.62 | 2023 | Trintellix |
| Idorsia Pharmaceuticals US INC | $22.56 | 2023 | Quviviq |
| Corium, LLC | $21.60 | 2025 | Azstarys |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.00 | 2023 | Jardiance |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $18.69 | 2024 | Qelbree |
| Mayne Pharma Commercial LLC | $15.23 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsay Dyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.